CL2020000907A1 - Terapias de combinación y usos de las mismas. - Google Patents
Terapias de combinación y usos de las mismas.Info
- Publication number
- CL2020000907A1 CL2020000907A1 CL2020000907A CL2020000907A CL2020000907A1 CL 2020000907 A1 CL2020000907 A1 CL 2020000907A1 CL 2020000907 A CL2020000907 A CL 2020000907A CL 2020000907 A CL2020000907 A CL 2020000907A CL 2020000907 A1 CL2020000907 A1 CL 2020000907A1
- Authority
- CL
- Chile
- Prior art keywords
- combination therapies
- immune response
- prevent tumor
- induce
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762569239P | 2017-10-06 | 2017-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000907A1 true CL2020000907A1 (es) | 2020-08-14 |
Family
ID=64051695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000907A CL2020000907A1 (es) | 2017-10-06 | 2020-04-03 | Terapias de combinación y usos de las mismas. |
| CL2020002958A CL2020002958A1 (es) | 2017-10-06 | 2020-11-13 | Terapias de combinación y usos de las mismas. (divisional de solicitud 20200907) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002958A CL2020002958A1 (es) | 2017-10-06 | 2020-11-13 | Terapias de combinación y usos de las mismas. (divisional de solicitud 20200907) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11801240B2 (enExample) |
| EP (1) | EP3691685A1 (enExample) |
| JP (1) | JP2020536869A (enExample) |
| KR (1) | KR20200067164A (enExample) |
| CN (1) | CN111182923A (enExample) |
| AU (2) | AU2018346688A1 (enExample) |
| BR (1) | BR112020006845A2 (enExample) |
| CA (1) | CA3076859A1 (enExample) |
| CL (2) | CL2020000907A1 (enExample) |
| CO (1) | CO2020005223A2 (enExample) |
| EA (1) | EA202090655A1 (enExample) |
| IL (1) | IL273510A (enExample) |
| MA (1) | MA50618A (enExample) |
| MX (1) | MX2020003799A (enExample) |
| PH (1) | PH12020550400A1 (enExample) |
| SG (1) | SG11202002499TA (enExample) |
| WO (1) | WO2019071123A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TW202444417A (zh) * | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| MX2020005659A (es) * | 2017-12-06 | 2020-08-20 | Jiangsu Hengrui Medicine Co | Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. |
| EP3966782A2 (en) | 2019-05-06 | 2022-03-16 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| US20230123585A1 (en) * | 2020-03-03 | 2023-04-20 | The University Of Chicago | Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors |
| CN112007042B (zh) * | 2020-09-10 | 2023-02-21 | 中国医学科学院医学生物学研究所 | 阿糖胞苷与原癌蛋白c-FOS抑制剂在制备治疗白血病的产品中的应用 |
| CN112316149A (zh) * | 2020-11-11 | 2021-02-05 | 王海涛 | 一种治疗tp53突变的晚期难治性实体瘤的药物及应用 |
| IL303103A (en) * | 2020-11-27 | 2023-07-01 | Snbioscience Inc | A pharmaceutical composition that includes insoluble nanoparticles containing a camptothecin compound for the treatment of cancer and its combined treatment |
| KR20220085742A (ko) * | 2020-12-15 | 2022-06-22 | 칸트사이언스 주식회사 | 암 환자에서 혈관 신생 억제 및 항암제 치료 효과 증대용 조성물 |
| CN114748479B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
| WO2022152902A1 (en) * | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| KR20230135075A (ko) * | 2021-01-22 | 2023-09-22 | 멘두스 비.브이. | 종양 백신접종 방법 |
| CN115177621B (zh) * | 2021-04-02 | 2023-09-01 | 上海市第一人民医院 | Av-951在制备用于抑制或治疗甲状腺相关眼病的药物中的应用 |
| CN113101288B (zh) * | 2021-05-08 | 2026-03-31 | 中国人民解放军空军军医大学 | 一种协同增效治疗脊索瘤的组合药物及其用途 |
| JP2025501572A (ja) * | 2021-12-23 | 2025-01-22 | ボストン サイエンティフィック メディカル デバイス リミテッド | 化学塞栓用組成物とそれを使用する治療方法 |
| CN116077643B (zh) * | 2021-12-31 | 2025-02-11 | 成都金瑞基业生物科技有限公司 | 治疗和/或预防肺癌的联合用药物及应用 |
| CN114712515A (zh) * | 2022-03-30 | 2022-07-08 | 上海交通大学医学院附属瑞金医院 | 一种dll4抑制剂联合parp抑制剂在制备治疗卵巢癌药物中的应用 |
| CN115177594B (zh) * | 2022-07-04 | 2023-08-15 | 武汉大学中南医院 | 一种阿昔替尼药物制剂及其制备方法 |
| CN117462687A (zh) * | 2022-07-20 | 2024-01-30 | 清华大学 | 一种用于制备预防或治疗骨转移癌药物的组合物及其应用 |
| CN115154589B (zh) * | 2022-08-26 | 2024-04-09 | 山东大学 | 白藜芦醇联合成纤维细胞生长因子1在缓解蒽环类药物诱导的心脏及肝脏毒性中的应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2059571T3 (es) | 1988-01-19 | 1994-11-16 | Takeda Chemical Industries Ltd | Fumagilina como agente angiostatico. |
| DE68915900T2 (de) | 1988-09-01 | 1994-11-24 | Childrens Medical Center | Angiogenese hemmendes Mittel. |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20090275619A1 (en) | 2006-04-03 | 2009-11-05 | BOUERES Julia | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| AU2008321382A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| WO2009064738A2 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| AR075239A1 (es) | 2009-02-04 | 2011-03-16 | Bipar Sciences Inc | Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| EP3327148B1 (en) | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| DK2928865T3 (en) | 2012-12-07 | 2018-06-18 | Merck Sharp & Dohme | BIOCATALYTIC TRANSAMINATION PROCEDURE |
| WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
| US20150071910A1 (en) | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA2931181C (en) | 2013-12-09 | 2023-01-24 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| JP6663350B2 (ja) | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー，インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
| US20170175197A1 (en) | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| JP6648040B2 (ja) | 2014-05-28 | 2020-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 |
| US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| PL3277321T3 (pl) | 2015-04-01 | 2024-11-18 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3) |
| WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| CN108883115A (zh) | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | 用parp抑制剂治疗小细胞肺癌 |
| WO2017142871A1 (en) | 2016-02-15 | 2017-08-24 | Astrazeneca Ab | Methods comprising fixed intermittent dosing of cediranib |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
| MA50677A (fr) | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
| CN110049777A (zh) | 2016-11-01 | 2019-07-23 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| AU2018205401B2 (en) | 2017-01-09 | 2025-01-02 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| EP3606523A1 (en) | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TWI791519B (zh) | 2017-04-27 | 2023-02-11 | 美商提薩羅有限公司 | 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途 |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| TW201929902A (zh) | 2017-12-27 | 2019-08-01 | 美商提薩羅有限公司 | 治療癌症之方法 |
| BR112020015909A2 (pt) | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
| EA201992594A1 (ru) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | Комбинированные терапии для лечения рака |
| US11970530B2 (en) | 2020-08-13 | 2024-04-30 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-10-05 US US16/754,083 patent/US11801240B2/en active Active
- 2018-10-05 EP EP18796190.9A patent/EP3691685A1/en not_active Withdrawn
- 2018-10-05 KR KR1020207012376A patent/KR20200067164A/ko not_active Ceased
- 2018-10-05 AU AU2018346688A patent/AU2018346688A1/en not_active Abandoned
- 2018-10-05 CN CN201880065336.2A patent/CN111182923A/zh active Pending
- 2018-10-05 JP JP2020519286A patent/JP2020536869A/ja active Pending
- 2018-10-05 CA CA3076859A patent/CA3076859A1/en active Pending
- 2018-10-05 WO PCT/US2018/054606 patent/WO2019071123A1/en not_active Ceased
- 2018-10-05 SG SG11202002499TA patent/SG11202002499TA/en unknown
- 2018-10-05 EA EA202090655A patent/EA202090655A1/ru unknown
- 2018-10-05 MX MX2020003799A patent/MX2020003799A/es unknown
- 2018-10-05 BR BR112020006845-4A patent/BR112020006845A2/pt not_active Application Discontinuation
- 2018-10-05 MA MA050618A patent/MA50618A/fr unknown
-
2020
- 2020-03-23 IL IL273510A patent/IL273510A/en unknown
- 2020-04-03 CL CL2020000907A patent/CL2020000907A1/es unknown
- 2020-04-03 PH PH12020550400A patent/PH12020550400A1/en unknown
- 2020-04-27 CO CONC2020/0005223A patent/CO2020005223A2/es unknown
- 2020-11-13 CL CL2020002958A patent/CL2020002958A1/es unknown
-
2022
- 2022-03-21 AU AU2022201944A patent/AU2022201944A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020006845A2 (pt) | 2020-10-06 |
| CN111182923A (zh) | 2020-05-19 |
| AU2022201944A1 (en) | 2022-04-14 |
| SG11202002499TA (en) | 2020-04-29 |
| WO2019071123A1 (en) | 2019-04-11 |
| EP3691685A1 (en) | 2020-08-12 |
| US11801240B2 (en) | 2023-10-31 |
| EA202090655A1 (ru) | 2020-12-07 |
| MX2020003799A (es) | 2020-11-06 |
| KR20200067164A (ko) | 2020-06-11 |
| MA50618A (fr) | 2020-08-12 |
| CL2020002958A1 (es) | 2021-03-05 |
| CA3076859A1 (en) | 2019-04-11 |
| PH12020550400A1 (en) | 2021-03-08 |
| IL273510A (en) | 2020-05-31 |
| CO2020005223A2 (es) | 2020-05-15 |
| US20200306236A1 (en) | 2020-10-01 |
| AU2018346688A1 (en) | 2020-04-23 |
| JP2020536869A (ja) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020005223A2 (es) | Terapias de combinación y usos de las mismas | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CR20220325A (es) | Fluoroalquil-oxadiazoles y sus usos | |
| CO2020007142A2 (es) | Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus | |
| MX383130B (es) | Composiciones que comprenden cepas bacterianas del genero megasphaera y sus usos. | |
| CL2017001464A1 (es) | Modulación inmunológica | |
| MX2017007148A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
| MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
| CL2021001432A1 (es) | Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn | |
| CL2015002807A1 (es) | Terapia de combinación | |
| PY1947754A (es) | Piridinil y pirazinil-(aza)indolsulfonamidas | |
| UY35464A (es) | Inhibidores covalentes de kras g12c. | |
| MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| ECSP16072034A (es) | Inhibidores de diacilglicerol aciltransferasa 2 para alteraciones metabólicas y desórdenes relacionados | |
| MX2015012054A (es) | Inhibidores covalentes de kras g12c. | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| MX2019007892A (es) | Compuestos inhibidores de metaloenzimas. | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX2017004288A (es) | Medio de induccion y metodos para el cultivo de y terapias con celulas madre. |